Y-MABS THERAPEUTICS INC (YMAB) Stock Price, Forecast & Analysis
USA - NASDAQ:YMAB - US9842411095 - Common Stock
YMAB Key Statistics, Chart & Performance
The current stock price of YMAB is 8.61 USD. In the past month the price increased by 1.06%. In the past year, price decreased by -37.29%.
YMAB Latest News, Press Relases and Analysis
YMAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About YMAB
Company Profile
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Company Info
Y-MABS THERAPEUTICS INC
202 Carnegie Center, Suite 301
Princeton NEW JERSEY 10169 US
CEO: Claus Juan Moller San Pedro
Employees: 104
Phone: 16468858505
Y-MABS THERAPEUTICS INC / YMAB FAQ
What does YMAB do?
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
What is the current price of YMAB stock?
The current stock price of YMAB is 8.61 USD. The price increased by 0.23% in the last trading session.
What is the dividend status of Y-MABS THERAPEUTICS INC?
YMAB does not pay a dividend.
What is the ChartMill rating of Y-MABS THERAPEUTICS INC stock?
YMAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for Y-MABS THERAPEUTICS INC?
Y-MABS THERAPEUTICS INC (YMAB) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for Y-MABS THERAPEUTICS INC?
Y-MABS THERAPEUTICS INC (YMAB) has a market capitalization of 391.24M USD. This makes YMAB a Small Cap stock.
YMAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to YMAB. When comparing the yearly performance of all stocks, YMAB is one of the better performing stocks in the market, outperforming 85.61% of all stocks.
YMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to YMAB. While YMAB has a great health rating, there are worries on its profitability.
YMAB Financial Highlights
Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.96% | ||
| ROE | -25.4% | ||
| Debt/Equity | 0 |
YMAB Forecast & Estimates
16 analysts have analysed YMAB and the average price target is 8.2 USD. This implies a price decrease of -4.75% is expected in the next year compared to the current price of 8.61.
For the next year, analysts expect an EPS growth of -24.97% and a revenue growth -5.98% for YMAB